Valdiléa G. Veloso

ORCID: 0000-0002-6622-3165
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV/AIDS Research and Interventions
  • HIV, Drug Use, Sexual Risk
  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • HIV-related health complications and treatments
  • Sex work and related issues
  • Adolescent Sexual and Reproductive Health
  • Pneumocystis jirovecii pneumonia detection and treatment
  • LGBTQ Health, Identity, and Policy
  • Liver Disease Diagnosis and Treatment
  • Syphilis Diagnosis and Treatment
  • Hepatitis C virus research
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Tuberculosis Research and Epidemiology
  • Cervical Cancer and HPV Research
  • Hepatitis B Virus Studies
  • Poxvirus research and outbreaks
  • Herpesvirus Infections and Treatments
  • Reproductive tract infections research
  • Viral-associated cancers and disorders
  • Long-Term Effects of COVID-19
  • Genital Health and Disease
  • Antifungal resistance and susceptibility
  • Science and Education Research

Fundação Oswaldo Cruz
2016-2025

Instituto Evandro Chagas
2016-2025

Instituto Nacional de Saúde
2022-2024

National Institute of Infectious Diseases
2021-2023

Faculdades Oswaldo Cruz
2022-2023

Creative Commons
2023

Academia Nacional de Medicina
2023

Secretaria de Ciência, Tecnologia e Inovação
2023

Ministério da Saúde
2022

Sexual Health Clinic
2022

Antiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing for initiation of ART when diagnosed various levels immune compromise not known.We conducted an open-label, randomized study comparing earlier (within 2 weeks after tuberculosis) later (between 8 and 12 HIV-1 CD4+ T-cell counts less than 250 per cubic millimeter suspected tuberculosis. The primary end point was proportion who survived...

10.1056/nejmoa1013607 article EN New England Journal of Medicine 2011-10-19

The safety and efficacy of adding antiretroviral drugs to standard zidovudine prophylaxis in infants mothers with human immunodeficiency virus (HIV) infection who did not receive antenatal therapy (ART) because late identification are unclear. We evaluated three ART regimens such infants.

10.1056/nejmoa1108275 article EN New England Journal of Medicine 2012-06-21
Beatriz Grinsztejn Brenda Hoagland Ronaldo I. Moreira Esper G. Kallás José Valdez Madruga and 69 more Silvia Pereira Goulart Iuri Costa Leite Lucilene Freitas Luana M S Martins Thiago S. Torres Ricardo Vasconcelos Raquel B. De Boni Peter L. Anderson Albert Liu Paula M. Luz Valdiléa G. Veloso Valvina Madeira Adão Paulo Ricardo de Alencastro Ana Paula Amaral Toni Araújo Denivalda Araújo Daniel Artur Bertevello Cristiane Bressani Sandra Wagner Cardoso Robério Alves Carneiro R F de Carvalho Natália B. Cerqueira Leandro Cocolato Marcus Vinícius M. da Costa Rosângela Vitória Soares da Silva Maria Cândida de Souza Dantas Cristiane R. V. Castro Karine Milani da Silva Dias Camila Sunaitis Donini Aline Tatiane Lumertz dos Anjos Arlene Augusta dos Santos Rita de Cássia Elias Estrela Nilo Martinez Fernandes Lilian Ferrari Josias Freitas Tatiane da Silva Gomes Maura L Gonzalez Raphaela Goulart José Roberto Granjeiro Marcus Lacerda Priscilla de Lima e Menezes Gustavo Mizuno Laylla Monteiro Issler Moraes Carlos Otávio Fiúza Moreira Denise Sales Mourão Zelinda Bartolomei Nakagawa Sandro Nazer Maria Angelica Alcalá Neves Roberta Schiavon Nogueira Fatuma Odongo Tiago Jordão Porto Gladys Villas Boas do Prado Marcia Puerro Gisele N. Reis Valéria Ribeiro Charlene Rocha Camila Rodrigues Rafael S. Salles Mariana M. Sauer Taís Nóbrega de Sousa Celso Oliveira Tavares Claudia Satiko Tomiyama Helena Tomiyama Desirée Vieira Vinícius Vieira Larissa M. Villela Daniel M. McMahon Waite Nélio Zuccaro

10.1016/s2352-3018(18)30008-0 article EN The Lancet HIV 2018-02-18

BACKGROUNDAlthough convalescent plasma has been widely used to treat severe coronavirus disease 2019 (COVID-19), data from randomized controlled trials that support its efficacy are limited.METHODSWe conducted a randomized, double-blind, trial among adults hospitalized with and critical COVID-19 at 5 sites in New York City (USA) Rio de Janeiro (Brazil). Patients were 2:1 receive single transfusion of either or normal control plasma. The primary outcome was clinical status 28 days following...

10.1172/jci150646 article EN Journal of Clinical Investigation 2021-05-11

Obesity rates are increasing among HIV-infected individuals, but risk factors for obesity development on ART remain unclear.In a cohort of adults in Rio de Janeiro, Brazil, we aimed to determine before and after initiation analyse ART.We retrospectively analysed data from individuals initiating between 2000 2015. BMI was calculated at baseline (time initiation). Participants who were non-obese had ≥90 days exposure followed until the or end follow-up. incidence estimated using Poisson...

10.1093/jac/dky145 article EN Journal of Antimicrobial Chemotherapy 2018-03-28

Syphilis infection may potentiate transmission of human immunodeficiency virus (HIV). We sought to determine the extent which HIV acquisition was associated with syphilis within an preexposure prophylaxis (PrEP) trial and whether emtricitabine/tenofovir (FTC/TDF) modified that association.The Preexposure Prophylaxis Initiative (iPrEx) study randomly assigned 2499 HIV-seronegative men transgender women who have sex (MSM) receive oral daily FTC/TDF or placebo. prevalence at screening incidence...

10.1093/cid/ciu450 article EN cc-by-nc-nd Clinical Infectious Diseases 2014-06-13

Daily preexposure prophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the risk of human immunodeficiency virus (HIV) acquisition. Initiation TDF bone mineral density (BMD) in HIV-infected people. We report effect FTC/TDF on BMD HIV-seronegative men who have sex transgender women.Dual-energy X-ray absorptiometry was performed at baseline 24-week intervals a substudy iPrEx, randomized, double-blind, placebo-controlled trial PrEP. Plasma...

10.1093/cid/civ324 article EN Clinical Infectious Diseases 2015-04-23

Tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis decreases sexual acquisition of HIV infection. We sought to evaluate the renal safety TDF in HIV-uninfected persons.The Iniciativa Profilaxis Pre-Exposición (iPrEx) study randomly assigned 2499 HIV-seronegative men and transgender women who have sex with (MSM) receive oral daily coformulated emtricitabine (FTC/TDF) or placebo. Serum creatinine phosphorus during randomized treatment after discontinuation were measured, clearance...

10.1097/qad.0000000000000156 article EN cc-by-nc-nd AIDS 2014-02-05

We describe temporal trends in the mortality rates and factors associated with AIDS non-AIDS related at Evandro Chagas Clinical Research Institute (IPEC), Oswaldo Cruz Foundation (FIOCRUZ).Adult patients enrolling from 1986 through 2009 a minimum follow up of 60 days were included. Vital status was exhaustively checked using patients' medical charts, active contact individuals family members by linkage Rio de Janeiro Mortality database previously validated algorithm. The CoDe protocol used...

10.1371/journal.pone.0059768 article EN cc-by PLoS ONE 2013-04-05

We conducted a web-based survey to understand the impact of social distancing measures on Brazilian MSM and transgender/non-binary lives. A total 3486 respondents were included in this analysis great majority cismen (98%). The median age was 32 years (IQR: 27-40), 44% non-white, 36% low schooling 38% income. Most participants reported HIV negative/unknown status (77%). Participants on-PrEP more condomless anal sex than those off-PrEP. Conversely, 24% off-PrEP at substantial HIV-risk....

10.1007/s10461-020-02984-1 article EN other-oa AIDS and Behavior 2020-07-31

Abstract Introduction : The efficacy of pre‐exposure prophylaxis (PrEP) in preventing sexual acquisition human immunodeficiency virus (HIV) is well established. Little known about the feasibility PrEP implementation middle‐income settings with concentrated epidemics among men who have sex (MSM) and transgender women (TGW). Methods Brasil a prospective, multicentre, open‐label demonstration project assessing delivery context Brazilian Public Health System. HIV‐uninfected MSM TGW 3 referral...

10.7448/ias.20.1.21472 article EN cc-by Journal of the International AIDS Society 2017-01-01

OBJECTIVE To estimate the seroprevalence of antibodies to SARS-CoV-2 among blood donors in state Rio de Janeiro, Brazil. METHODS Data were collected on 2,857 from April 14 27, 2020. This study reports crude prevalence SARS-CoV-2, population weighted for state, and adjusted test sensitivity specificity. Logistic regression models used establish correlates prevalence. For analysis, we considered collection period site, sociodemographic characteristics, place residence. RESULTS The proportion...

10.11606/s1518-8787.2020054002643 article EN cc-by Revista de Saúde Pública 2020-07-06

HIV disproportionally affects key populations including men who have sex with (MSM). prevalence among MSM varies from 17% in Brazil and Mexico to 13% Peru, whereas it is below 0.5% for the general population each country. Pre-exposure prophylaxis (PrEP) emtricitabine/tenofovir being implemented context of combination prevention. Reports on willingness use PrEP started emerge over last few years. Previously reported factors associated include awareness, higher sexual risk behavior, previous...

10.2196/13771 article EN cc-by JMIR Public Health and Surveillance 2019-05-16

COVID-19 public health responses such as social distancing and community containment measures protocols are critical to preventing containing the spread of coronavirus. Brazil accounts for almost half Latin American HIV cases Rio de Janeiro is city with second largest number AIDS. Clinical appointments pharmacy antiretroviral refills may be impaired due restricted traffic possible lockdowns, people living those using PrEP from accessing needed antiretrovirals. We hereby describe telemedicine...

10.1016/j.bjid.2020.05.004 article EN cc-by-nc-nd The Brazilian Journal of Infectious Diseases 2020-05-31
Coming Soon ...